Details for Patent: 9,782,402
✉ Email this page to a colleague
Which drugs does patent 9,782,402 protect, and when does it expire?
Patent 9,782,402 protects SUBLOCADE and is included in one NDA.
This patent has forty-three patent family members in thirty countries.
Summary for Patent: 9,782,402
| Title: | Injectable composition comprising buprenorphine |
| Abstract: | The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis. |
| Inventor(s): | Norton; Richard L. (Fort Collins, CO), Watkins; Andrew (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO) |
| Assignee: | Indivior UK Limited (Berkshire, GB) |
| Application Number: | 15/334,000 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; |
Drugs Protected by US Patent 9,782,402
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE | ⤷ Sign Up | |||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE | ⤷ Sign Up | |||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE | ⤷ Sign Up | |||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE | ⤷ Sign Up | |||
| Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-002 | Nov 30, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,782,402
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011263478 | ⤷ Sign Up | |||
| Brazil | 112012031290 | ⤷ Sign Up | |||
| Canada | 2801676 | ⤷ Sign Up | |||
| Chile | 2012003462 | ⤷ Sign Up | |||
| China | 103079544 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
